



We're liberating millions from allergies.



THERE ARE

50 million people who suffer from allergies each year

WHO

Use chemical filled drugs daily just to combat symptoms for a short term

BUT

Continue to suffer from worsening symptoms and are at risk of autoimmune disorders








AllerPops feeds oral probiotics and corrects the cause of allergies.

The cause of allergies is oral probiotic deficiency.

Allergies worsen if you do not have enough beneficial bacteria in your mouth. These bacteria pacify the immune system, preventing pointless attacks on harmless substances.





Relief lasting months to years.

Additional benefits include stopping/slowing progress of allergies and lowering risk of autoimmune diseases.



_OUR SOLUTION

We're drug free, allnatural, and made with FDA approved food ingredients.



_EFFECTIVE

AllerPops Relieve Symptoms

AllerPops are Highly effective in Relieving Allergy Symptoms

Below is a chart that shows how many people report relief to specific symptoms

94.5%

of users feel relief from

Nasal Congestion

89.5%

of users feel relief from

Nasal Discharge or Sneezing

86%

of users feel relief from

Watery/Red Eyes

81.3%

of users feel relief from

Headaches

80%

of users feel relief from

Sore Throat

76.5%

of users feel relief from

Wheezing/Asthma

73.9

of users feel relief from

Coughing

69.2%

of users feel relief from

Eczema

53.3%

of users feel relief from

Arthritis/Muscle Aching



Thousands of customers are satisfied.





Godsend for my son and me."

—Thomas G.



"I would recommend trying this product."

-Robert R.











INTRODUCING



CONFIDENTIAL AND PROPRIETARY / COPYRIGHT 2021 / ALL RIGHTS RESERVED





Brand

Treat the cause of allergies, beyond symptomatic intervention.



Product

AllerPops provides allergy sufferers relief that lasts for months to years,



Mission

Liberate millions from allergies.
Allow people to live hominy with mother nature.



Our industry is primed for growth with little competition.

\$18B \$40B 40% **50M** 6th The annual value Spent annually in Leading cause of Americans suffer of the allergy Children suffer chronic desease in from airborne the American from allergies. market allergy market. allergies the United States. worldwide by 2025

Symptomatic treatment:























Causal treatment:







_MARKETING

Advertising our scientific breakthrough by promoting media coverage of clinical trial.



DTC

Jump start

Our clinical trial in 2021 will confirm the scientific work behind AllerPops. We will promote media coverage and jumpstart the sales.

International market opens

2021: Canada and Mexico

2022: EU and Japan 2023: China and Korea

Incentives

Free Shipping in US, Hassle-free returns for 90 Days White Glove Customer Service

Awards Program

Bumper sticker
BAAA to encourage social share

Backend


Powered by Woocommerce High-Touch, Dual-Location 3PL Social Impact Program Management

Target KPIs

AOV \$28 GM > 80% CAC \$10

Direct to Customer Sales Sustain Growth

3 YEAR UNIT SALES SUMMARY	2021	2022	2023
Total Units	89,000	252,000	1,000,000
Revenue	\$1,442,000	\$3,472,000	\$15,000,000
NET PROFIT	\$448,000	\$1,560,000	\$5,000,000








The multichannel opportunity is vast.

Retail partnerships and B2B sales will accelerate growth..





PROFIT AND LOSS

	2018	2019
Income		
Total product sales	22,329.83	58,360.04
Cost of goods sold	4,035.09	8,327.46
Gross profit	16,514.06	50,032.58
Expenses		
Advertising & marketing	106,816.20	122,136.71
Operating expenses	53,751.52	40,730.81
Rent & utilities	22,927.42	23,830.10
Total expenses	181,625.20	186,697.62
Net income	-163,330.46	-136,665.04





Risks	Mitigation
The allergy relief marketplace has highly competitive players.	Raise more fund through Wefunder and other sources after the clinical trial for faster expansion.
AllerPops takes a completely novel approach to allergy relief.	Education through our website, media, and conferences, as well as targeting early adopters.
A clinical trial by a third party may fail due to unforeseeable reasons.	Form a study team with qualified researchers. Establish a robust plan.
The FDA may require the company to provide more data from a bigger study.	Communicate with FDA early and prepare for an expanded study.
Global trading relationships may interfere with international expansion.	Consider different entry strategies such as direct, partnership, royalty.
Our future success depends on the efforts of a small management team.	We have identified a candidate for COO and are looking for CMO.





We have a team that's been there before.



Mandy Marksteiner Marketing Strategist





Joe Hipple Strategic Advisor, Finance

Cliff Shunsheng Han Founder / CEO

Dr. Cliff Han

AllerPops founder and CEO



- 28 years of biological research.
- Part of the Human Genome Project.
- 10 years in project management and quality control.
- Trained physician and psychiatrist










Joe Hipple

Strategic Advisor, Finance



- CEO/Founder of F.E.A. | StrategiesGroup, LLC
- Vice President and Director of CBS Broadcasting Group.
- Founder and COO of Black Hawk
 Cable Communications
- Vice President and Area Manager of Comcast Corporation









We are inviting passionate investors to join us.

Own a piece of AllerPops, liberate millions from allergies.

Wefunder first round target raise -- \$500,000

Clinical trials and publication

Marketing and public relations

Inventory and product development

Legal fees for patents and FDA application

Office rent, supplies and equipment

Wefunder fees and financial consulting

Market expansion timeline:

1st & 2nd qtr. 2021 Clinical trial Marketing at a limited scope

3rd qtr. 2021 Publication of the clinical trial 4th qtr. 2021 Promotion of our clinical trial 2022
Nation-wide branding and marketing

CONFIDENTIAL | These are forward looking projections and are not guaranteed.



